Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03359876 · ClinicalTrials.gov registry record
Clinical Outcomes Among Non-valvular Atrial Fibrillation Patients With Renal Dysfunction
A clinical trial of Atrial Fibrillation, sponsored by Bayer.
- Completed
- Registry status
- 16,000
- Enrollment target
- 1
- Study location
NCT03359876: Completed study of Atrial Fibrillation, sponsored by Bayer.
NCT03359876 is a study of Atrial Fibrillation that has completed, run by Bayer. The registered enrollment target is 16,000 participants, above the 2,918-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (448% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03359876, a study of Atrial Fibrillation, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- 16,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of the study is to evaluate the effectiveness and safety of the reduced dose rivaroxaban (15 mg once daily) as compared to warfarin in non-valvular atrial fibrillation (NVAF) patients with renal dysfunction in routine clinical practice. The study has a retrospective design, and will be conducted in the US Truven Health MarketScan Commercial Claims and Medicare Supplemental Databases
Primary Outcome
The study outcomes will be defined based on the International Classification of Diseases, 9th- and 10th-revision, Clinical Modification (ICD-9/10-CM) diagnosis codes, Current Procedural Technology, 4th-revision (CPT-4) and Healthcare Common Procedure Coding System (HCPCS) procedure codes
Conditions Studied
Interventions
- DRUG Rivaroxaban (Xarelto, BAY59-7939)
- DRUG Warfarin sodium
Study Locations (1)
New Jersey
- US Truven MarketScan - Whippany
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16,000 participants |
| Start Date | 2017-12-01 |
| Est. Completion | 2019-03-29 |
What the finished NCT03359876 record still lists
NCT03359876 is an observational study that tracks outcomes without assigning an intervention. Its 16,000 participants enrollment target places it among the larger protocols in the corpus, above the 2,918-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (448% higher).
The record links to 1 condition, with Atrial Fibrillation appearing as the primary indexed condition, and to 2 interventions - of which Rivaroxaban (Xarelto, BAY59-7939) is the first listed.
NCT03359876 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT03359876 about?
NCT03359876 is a clinical study titled "Clinical Outcomes Among Non-valvular Atrial Fibrillation Patients With Renal Dysfunction". The objective of the study is to evaluate the effectiveness and safety of the reduced dose rivaroxaban (15 mg once daily) as compared to warfarin in non-valvular atrial fibrillation (NVAF) patients with renal dysfunction in routine clinical practice. The study has a retrospective design, and will be...
What is the current status of trial NCT03359876?
This trial is currently completed. The enrollment target is 16,000 participants. The study started on 2017-12-01. Estimated completion is 2019-03-29.
What conditions does trial NCT03359876 study?
This clinical trial studies the following conditions: Atrial Fibrillation.
What interventions are being tested in trial NCT03359876?
The interventions under investigation include: Rivaroxaban (Xarelto, BAY59-7939) (DRUG), Warfarin sodium (DRUG).
Who is sponsoring clinical trial NCT03359876?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03359876 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atrial Fibrillation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03359876's enrollment target sits among peer trials
16,000 9th of 202 higher than 194 of 202 other Atrial Fibrillation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atrial Fibrillation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Amiodarone for the Prevention of Atrial Fibrillation After Minimally Invasive Esophagectomy in Patients With Esophageal Cancer
RECRUITING · Phase 2
-
The Dynamics of Human Atrial Fibrillation
RECRUITING
-
Renal Denervation + PVI vs PVI Alone for Persistent AF
RECRUITING · NA
-
Pericardiotomy in Cardiac Surgery
RECRUITING · NA
-
CellFX® Nanosecond Pulsed Field Ablation (nsPFA)™ Cardiac Surgery Clamp System to Treat Atrial Fibrillation
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01737528 · 16,000 participants
STS/ACC Transcatheter Valve Therapy Registry (TVT Registry)
- NCT06380114 · 16,000 participants · NA
Stand Up 2 HPV: Standing Orders to Improve HPV Vaccination
- NCT05447806 · 15,732 participants · NA
Diabetes Clinical Decision Support
- NCT06951867 · 16,640 participants
Tezspire Cardiac Events PASS
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI